ALTANA will Submit Daxas-R- -Roflumilast- for European Approval in February 2004.Business Editors/Health/Medical Writers BAD HOMBURG, Germany--(BUSINESS WIRE)--Dec. 19, 2003 ALTANA AG (NYSE NYSE See: New York Stock Exchange :AAA AAA: see American Automobile Association. (Triple A) A common single-cell battery used in a myriad of electronic devices of all variety. Like its double A (AA) cousin, it provides 1.5 volts of DC power. When used in series, the voltage is multiplied. ) (FWB (Fixed Wireless Broadband) See fixed wireless. :ALT), Germany, announced today that its Pharmaceutical Division ALTANA Pharma, in partnership with Pfizer Inc., will submit the registration dossier for its respiratory drug Daxas(R) (Roflumilast) for European approval to the EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. (European Agency for the Evaluation of Medicinal Products) in February 2004. Daxas(R) is being developed as an oral, once-daily, anti-inflammatory, selective phosphodiesterase-4 (PDE4)-inhibitor for the treatment of COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) (chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. ) and asthma. "We are delighted that the approval process in Europe can be initiated. The efficacy and safety of Daxas(R) will provide an important option for patients suffering from COPD and asthma", said Dr. Hans-Joachim Lohrisch, Member of the Management Board of ALTANA AG and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ALTANA Pharma. Daxas(R) is being developed with Pfizer in the United States and other markets. A cooperation agreement has also been made with Tanabe Seiyaku in Japan. This press release contains forward-looking statements, i.e., current estimates or expectations of future events or future results. The forward-looking statements appearing in this press release include information on the planned submission of the registration dossier for Daxas(R) for approval in Europe. These statements are based on beliefs of ALTANA's management as well as assumptions made by and information currently available to ALTANA. Many factors that ALTANA is unable to predict with accuracy could cause ALTANA's actual results or performance to be materially different from those that may be expressed or implied by such forward-looking statements. Forward-looking statements speak only as of the date they are made. ALTANA does not intend, and does not assume any obligation, to update forward-looking statements to reflect facts, circumstances or events that have occurred or changed after such statements have been made. This press release is also available on the Internet at www.altana.de. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion